Authors

Charles A. Powell, MD, MBA, Mount Sinai-National Jewish Health Respiratory Institute

Latest:

Monitoring Patients for Interstitial Lung Disease

Experts discuss the optimal monitoring of patients to identify interstitial lung disease early and how to intervene.

Katie Kelley, MD

Latest:

Patient Profile 3: Advanced HCC Treated With Cabozantinib in Second Line

Centering discussion on the final patient profile, panelists consider how they select optimal therapy in the second-line setting of advanced hepatocellular carcinoma.

Cheryl Saenz, MD

Latest:

Dr. Saenz on the Need for Ongoing Research Efforts in Cervical Cancer

Cheryl Saenz, MD, discusses the need for ongoing research efforts in cervical cancer.

Huma Q. Rana, MD, MPH

Latest:

Dr. Rana on Using Age at Diagnosis to Guide the Utility of Genetic Testing in Prostate Cancer

Huma Q. Rana, MD, MPH, discusses the use of age at diagnosis to guide the utility of genetic testing in men with prostate cancer.

Devon Womack

Latest:

Providing Timely Cancer Care Access Is Crucial Amid Growing Patient Volume

A closer look at some of the approaches being used across The US Oncology Network to improve patient access can provide helpful insight into how practices can meet the growing need for their services.

Hannah Walker-Mimms, MS

Latest:

Dr Walker-Mimms on Outcomes With Filanesib in Ewing and Clear Cell Sarcoma

Hannah Walker-Mimms, MS, discusses a study revealing that Ewing and clear cell sarcomas have increased sensitivity to filanesib over other cancer types.

Gautam Borthakur, MD

Latest:

Dr Borthakur on the SELECT MDS-1 Trial in Newly Diagnosed MDS

Gautam Borthakur, MD, discusses the ongoing phase 3 SELECT MDS-1 trial in patients with newly diagnosed myelodysplastic syndromes.

Akash Mukherjee, MD

Latest:

Current Treatment Perspectives for CAR T-Cell Therapy in R/R B-Cell Lymphoma

Chimeric antigen receptor T-cell therapy has proven to be an effective adoptive cellular therapy against relapsed/refractory B-cell lymphoma.

Sandra Mazzoni, DO

Latest:

Real-world Outcomes with Talquetamab

Panelists discuss how they manage talquetamab-specific toxicities including dysgeusia and nail/skin changes through patient preparation, dietary modifications with umami-rich foods, emollients, and extended dosing intervals.

UW School of Medicine

Latest:

UW Carbone Cancer Center Receives SPORE Designation, Federal Grant to Support Prostate Cancer Research

University of Wisconsin Carbone Cancer Center will be designated as a Specialized Program of Research Excellence, or SPORE, by the National Cancer Institute for research initiatives to advance new prostate cancer treatments.

Kate Baker, MD, MMHC

Kate Baker, MD, MMHC, is medical director of value-based care at Tennessee Oncology

Sally Lau, MD

Latest:

Dr Lau on Tarlatamab as Maintenance Therapy in Extensive-Stage SCLC

Sally Lau, MD, discusses the addition of tarlatamab to a PD-L1 inhibitor as first-line maintenance therapy for extensive-stage small cell lung cancer.

Nasser Khaled Altorki, MD

Latest:

Dr. Altorki on the Results of Post-Hoc Analyses of the IMpower010 Trial in NSCLC

Nasser Khaled Altorki, MD, discusses the results of post-hoc analyses of the phase 3 IMpower010 trial in non–small cell lung cancer.

Milind Javle, MD, The University of Texas MD Anderson Cancer Center

Latest:

The Investigational Pipeline for Advanced BTC

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss ongoing research efforts in advanced biliary tract cancer.

Hideaki Bando, MD, PhD

Hideaki Bando, MD, PhD is a medical oncologist in the Department of Gastroenterology and Gastrointestinal Oncology at the National Cancer Center Hospital East, in Japan.

Latest:

Dr Bando on Safety of TAS-102 in MRD+ Resected CRC

Hideaki Bando, MD, PhD, discusses the safety of trifluridine/tipiracil in patients with MRD following resection of CRC.

Pierre Gholam, MD

Latest:

Dr Gholam on Camrelizumab Plus Rivoceranib in Unresectable HCC

Pierre Gholam, MD, discusses findings from the phase 3 CARES-310 trial of camrelizumab plus rivoceranib in patients with unresectable hepatocellular carcinoma.

Arpit Rao, MD

Latest:

Dr. Rao on the Rationale of the CASPAR Trial in mCRPC

Arpit Rao, MD, discusses the rationale and importance of the phase 3 CASPAR trial in castration-resistant prostate cancer.

Julio Gutierrez, MD

Latest:

Safety Profiles of Available Therapies in Advanced HCC

Dr Ghassan K. Abou-Alfa explains the safety profiles of the discussed frontline therapy options for advanced HCC.

Afsaneh Barzi, MD, PhD

Latest:

Dr Barzi on the Real-World Use of Triplet Chemotherapies in mCRC

Afsaneh Barzi, MD, PhD, discusses the frontline use of FOLFOXIRI plus bevacizumab and subsequent therapies in patients with metastatic colorectal cancer.

Hans C. Lee, MD

Latest:

Dr Lee on the Significance of Longer-Term Data for Linvoseltamab in R/R Multiple Myeloma

Hans C. Lee, MD, discusses the significance of longer-term data for linvoseltamab from the LINKER-MM1 study in relapsed/refractory multiple myeloma.